Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMILE: Multifactorial Intervention of Primary Prevention in High Risk Subjects
NCT03654105Phase 2Active, not recruiting
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jul 2019
- Primary completion
- Dec 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cytisinicline and aspirin in lung cancer, Tobacco Use Disorder (TUD) and inflammation (4 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Change in chronic inflammatory status at 1 year. Started Jul 2019; status: active, not recruiting.
02
Drugs
cytisiniclineaspirin
03
Conditions
lung cancerTobacco Use Disorder (TUD)inflammation
Beyond the preview
Go deeper on NCT03654105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654105.